Endo International plc – (NASDAQ:ENDP) – Gabelli lifted their FY2021 EPS estimates for shares of Endo International plc – in a research note issued on Thursday, Zacks Investment Research reports. Gabelli analyst K. Kedra now forecasts that the company will post earnings of $4.70 per share for the year, up from their prior estimate of $4.65.
Endo International plc – (NASDAQ:ENDP) last announced its earnings results on Tuesday, February 28th. The company reported $1.77 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.63 by $0.14. The company earned $1.24 billion during the quarter, compared to the consensus estimate of $1.17 billion. Endo International plc – had a negative net margin of 3.32% and a positive return on equity of 15.95%. Endo International plc -‘s revenue was up 15.6% compared to the same quarter last year. During the same period last year, the firm earned $1.36 earnings per share.
COPYRIGHT VIOLATION WARNING: “FY2021 EPS Estimates for Endo International plc – (ENDP) Lifted by Analyst” was first published by Community Financial News and is owned by of Community Financial News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.com-unik.info/2017/04/21/endo-international-plc-endp-expected-to-post-fy2021-earnings-of-4-70-per-share-updated-updated.html.
Several other research firms have also recently issued reports on ENDP. Citigroup Inc cut shares of Endo International plc – from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $25.00 to $20.00 in a research note on Thursday, January 5th. Zacks Investment Research cut shares of Endo International plc – from a “hold” rating to a “sell” rating in a research report on Tuesday, January 3rd. Canaccord Genuity set a $14.00 target price on shares of Endo International plc – and gave the stock a “hold” rating in a research report on Wednesday, March 1st. Mizuho reissued a “buy” rating and issued a $17.00 target price (up from $15.00) on shares of Endo International plc – in a research report on Tuesday, February 28th. Finally, Oppenheimer Holdings Inc. reissued a “hold” rating on shares of Endo International plc – in a research report on Wednesday, March 1st. Thirteen investment analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Endo International plc – has a consensus rating of “Hold” and an average target price of $20.72.
Shares of Endo International plc – (NASDAQ:ENDP) traded down 1.81% during midday trading on Friday, reaching $10.29. 5,834,933 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $10.84 and its 200 day moving average price is $14.65. The stock’s market capitalization is $2.29 billion. Endo International plc – has a 1-year low of $9.70 and a 1-year high of $35.34.
In related news, Director Nancy J. Hutson sold 5,325 shares of Endo International plc – stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $10.82, for a total value of $57,616.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.70% of the stock is currently owned by insiders.
Hedge funds have recently modified their holdings of the company. Nationwide Fund Advisors raised its stake in shares of Endo International plc – by 400.0% in the first quarter. Nationwide Fund Advisors now owns 343,874 shares of the company’s stock worth $3,838,000 after buying an additional 275,101 shares during the period. Hartford Investment Management Co. bought a new stake in shares of Endo International plc – during the first quarter worth about $1,363,000. Americafirst Capital Management LLC bought a new stake in shares of Endo International plc – during the first quarter worth about $286,000. Macquarie Group Ltd. raised its stake in shares of Endo International plc – by 132.1% in the fourth quarter. Macquarie Group Ltd. now owns 6,500 shares of the company’s stock worth $107,000 after buying an additional 3,700 shares during the period. Finally, Norges Bank bought a new stake in shares of Endo International plc – during the fourth quarter worth about $26,929,000. Institutional investors and hedge funds own 95.50% of the company’s stock.
Endo International plc – Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
What are top analysts saying about Endo International plc -? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Endo International plc - and related companies.